WO2008093646A1 - Peptide susceptible d'activer une signalisation wnt - Google Patents

Peptide susceptible d'activer une signalisation wnt Download PDF

Info

Publication number
WO2008093646A1
WO2008093646A1 PCT/JP2008/051224 JP2008051224W WO2008093646A1 WO 2008093646 A1 WO2008093646 A1 WO 2008093646A1 JP 2008051224 W JP2008051224 W JP 2008051224W WO 2008093646 A1 WO2008093646 A1 WO 2008093646A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
amino acid
stem cell
activity
acid sequence
Prior art date
Application number
PCT/JP2008/051224
Other languages
English (en)
Japanese (ja)
Inventor
Masao Tanihara
Kazumi Kajiwara
Original Assignee
National University Corporation NARA Institute of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University Corporation NARA Institute of Science and Technology filed Critical National University Corporation NARA Institute of Science and Technology
Priority to JP2008556089A priority Critical patent/JPWO2008093646A1/ja
Publication of WO2008093646A1 publication Critical patent/WO2008093646A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un peptide ou l'un de ses sels doté d'un poids moléculaire relativement bas et qui est utile pour la régulation de la prolifération ou la différentiation d'une cellule souche, notamment une cellule souche neuronale ou une cellule souche hématopoïétique, ou le traitement du cancer, d'une maladie neurologique ou d'autres maladies telles que le diabète. L'invention concerne particulièrement un peptide de l'élément suivant (1) ou (2) ou l'un de ses sels : (1) un peptide comprenant la séquence d'acides aminés décrite dans SEQ ID NO:1 ; ou (2) un peptide comprenant la séquence d'acides aminés comportant la substitution, la délétion ou l'addition d'un ou plusieurs résidus d'acide aminé dans la séquence d'acides aminés décrite dans SEQ ID NO:1, et qui est doté d'au moins une activité de signalisation Wnt choisie parmi le groupe comprenant une activité d'induction de l'adhésion d'une cellule PC12, une activité favorisant la différentiation d'une cellule souche neurologique et une activité d'accélération de l'accumulation intracellulaire de β-caténine.
PCT/JP2008/051224 2007-02-01 2008-01-28 Peptide susceptible d'activer une signalisation wnt WO2008093646A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008556089A JPWO2008093646A1 (ja) 2007-02-01 2008-01-28 Ｗｎｔシグナル伝達系活性化ペプチド

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-023073 2007-02-01
JP2007023073 2007-02-01

Publications (1)

Publication Number Publication Date
WO2008093646A1 true WO2008093646A1 (fr) 2008-08-07

Family

ID=39673957

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051224 WO2008093646A1 (fr) 2007-02-01 2008-01-28 Peptide susceptible d'activer une signalisation wnt

Country Status (2)

Country Link
JP (1) JPWO2008093646A1 (fr)
WO (1) WO2008093646A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
JP2020506701A (ja) * 2017-01-26 2020-03-05 スロゼン， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032838A2 (fr) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methodes de traitement du cancer par inhibition de la signalisation de wnt
WO2005040347A2 (fr) * 2003-10-24 2005-05-06 California Institute Of Technology Procedes et compositions pour inhiber la croissance et la proliferation cellulaires

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004032838A2 (fr) * 2002-10-04 2004-04-22 The Regents Of The University Of California Methodes de traitement du cancer par inhibition de la signalisation de wnt
WO2005040347A2 (fr) * 2003-10-24 2005-05-06 California Institute Of Technology Procedes et compositions pour inhiber la croissance et la proliferation cellulaires
WO2005040351A2 (fr) * 2003-10-24 2005-05-06 California Institute Of Technology Compositions induisant la croissance et la differenciation cellulaire et procedes d'utilisation

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101285259B1 (ko) * 2011-08-04 2013-07-11 (주)케어젠 Ｗｎｔ 계열 유래 펩타이드 및 이의 용도
JP2014521685A (ja) * 2011-08-04 2014-08-28 ケアジェン カンパニー，リミテッド Ｗｎｔ系列由来のペプチド及びこれの用途
EP2740741A4 (fr) * 2011-08-04 2015-08-05 Caregen Co Ltd Peptide dérivé de la famille des wnt et ses utilisations
JP2016029061A (ja) * 2011-08-04 2016-03-03 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途
EP3037433A1 (fr) * 2011-08-04 2016-06-29 Caregen Co., Ltd. Peptides dérivés de la famille wnt et leurs utilisations
JP2017008030A (ja) * 2011-08-04 2017-01-12 ケアジェン カンパニー, リミテッドCaregen Co., Ltd. Ｗｎｔ系列由来のペプチド及びこれの用途
EP3121196A1 (fr) * 2011-08-04 2017-01-25 Caregen Co., Ltd. Peptides dérivés de la famille wnt et leurs utilisations
US11993645B2 (en) 2017-01-11 2024-05-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions comprising R-Spondin (RSPO) surrogate molecules
JP2020506701A (ja) * 2017-01-26 2020-03-05 スロゼン， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
JP7305543B2 (ja) 2017-01-26 2023-07-10 スロゼン オペレーティング， インコーポレイテッド 組織特異的Ｗｎｔシグナル増強分子およびその使用
US11958891B2 (en) 2017-01-26 2024-04-16 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses thereof

Also Published As

Publication number Publication date
JPWO2008093646A1 (ja) 2010-05-20

Similar Documents

Publication Publication Date Title
EP1778842B8 (fr) Compositions et procedes d'utilisation pour le facteur de stimulation de colonies de monocytes, de granulocytes et de cellules dendritiques dans le traitement de maladies
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2455461A3 (fr) Variantes de lipase pour utilisation pharmaceutique
EP2573109A3 (fr) Vaccins de peptide avec Seq Id 101, 80 or 100 pour cancers exprimant des antigènes associés aux tumeurs
WO2012142320A3 (fr) Compositions et méthodes de prévention ou de traitement de maladies, d'affections ou de processus caractérisés par une prolifération aberrante des fibroblastes et un dépôt de matrice extracellulaire
MX2008009493A (es) Peptido novedoso y uso del mismo.
EP2940042A3 (fr) Fragments de peptides pour induire la synthèse de protéines de matrice extracellulaire
EP2039367A4 (fr) Agent prophylactique/thérapeutique pour maladie neurodégénérative
EP2508601A3 (fr) Peptides Tem8 et vaccins les comportant
WO2007093177A3 (fr) Fragments de peptides derives de la metallothioneine
WO2002061076A1 (fr) Proteine associee a l'adiponectine
WO2008093646A1 (fr) Peptide susceptible d'activer une signalisation wnt
WO2006028561A3 (fr) Nouveaux polypeptides fabi purifies issus de fransicella tularensis
WO2007093848A3 (fr) Nouveaux polypeptides purifiés issus de helicobacter pylori
WO2007071248A8 (fr) Peptides derives de la famille des proteines s-100 favorisant la survie neuritogene et neuronale
WO2009068042A3 (fr) Nouveaux peptides issus de ncam (fgls)
WO2008099928A1 (fr) Protéine placentaire ayant une action de régulation d'activité de protéase et son gène apparenté
CA2530731A1 (fr) Peptide presentant une activite d'inhibition de l'apoptose
WO2005005469A3 (fr) Nouveaux polypeptides purifies provenant du staphylocoque dore
WO2003097789A3 (fr) Nouveaux polypeptides purifies issus de pseudomonas aeruginosa
WO2009069546A1 (fr) Agent thérapeutique ou prophylactique, procédé de détection et agent de détection pour le syndrome métabolique, et procédé de criblage d'un composé candidat pour un agent thérapeutique pour le syndrome métabolique
WO2004013167A3 (fr) Nouveaux polypeptides purifies issus d'enterococcus faecalis
WO2008075174A3 (fr) Polypeptide du type protéine membranaire lysosomale (lamp), ses ligands et son utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes chez l'homme
WO2006136982A3 (fr) Polypeptide isole de la proteine de controle du complement du virus vaccinal de recombinaison (hrvcp)
WO2003087141A3 (fr) Nouveaux polypeptides purifies d'escherichia coli

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704033

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2008556089

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08704033

Country of ref document: EP

Kind code of ref document: A1